GO
Loading...

Enter multiple symbols separated by commas

Valeant Pharmaceuticals International Inc

More

  • TORONTO, July 2- Royal Bank of Canada was the top adviser on Canadian equity issues in the first half of 2015 as acquisitions and the energy industry's need to strengthen balance sheets fueled record high deal flow, according to data from Thomson Reuters. The investment banking units of Bank of Montreal and Canadian Imperial Bank of Commerce rounded out the top...

  • After-hours buzz: Nike, Micron, Synnex & more Thursday, 25 Jun 2015 | 5:39 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Check out the companies making headlines after the bell Thursday: Nike, Micron, Synnex & more.

  • June 25- Canada- based drugmaker Valeant Pharmaceuticals International Inc has approached to buy Zoetis Inc, an animal-health company, the Wall Street Journal reported. Shares of Zoetis, whose pipeline includes medicines and vaccines for pets and livestock, were up 2 percent at $56.65 in extended trading. The decision came a month after Bill Ackman's Pershing...

  • Valeant offers to buy Zoetis - WSJ Thursday, 25 Jun 2015 | 4:30 PM ET

    June 25- Canada- based drugmaker Valeant Pharmaceuticals International Inc has approached to buy Zoetis Inc, an animal-health company, the Wall Street Journal reported. Zoetis, spun off from Pfizer Inc in 2013, was valued at $24.85 billion as of Thursday's close, according to Thomson Reuters data. It was not clear what Zoetis's reaction to the approach was, if any,...

  • Zoetis halted for volatility on takeover report Thursday, 25 Jun 2015 | 3:58 PM ET
    Zoetis

    Animal health behemoth Zoetis was halted for volatility on Thursday.

  • Hedge funds top 2014 gain with these stocks Thursday, 18 Jun 2015 | 9:35 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Hedge fund returns in the first five months of the year have already surpassed the total for 2014. Here's how they're doing it.

  • Valeant names McKinsey merger expert as its next CFO Thursday, 11 Jun 2015 | 9:49 AM ET

    June 11- Valeant Pharmaceuticals International Inc has again reached into the ranks of business advisory firm McKinsey& Co to hire a senior executive, naming Robert Rosiello as its next chief financial officer on Thursday. Valeant's shares rose about 1 percent in morning trading in New York and Toronto. The stock had declined in pre-market activity as...

  • Cramer: Serial acquirers raking in major dough Friday, 5 Jun 2015 | 6:49 PM ET
    Actavis pharmaceuticals

    As Jim Cramer worries about the economy slowing, he found four companies that are in the sweet spot to generate major cash for your portfolio.

  • McDonald's, other stocks hedge funds are buying Thursday, 28 May 2015 | 3:06 PM ET

    One research firm believes it found a way to capture winning plays from the filings of hundreds of hedge funds.

  • May 20- Valeant Pharmaceuticals International Inc is in talks to buy Egyptian drugmaker Amoun Pharmaceutical Co to expand its veterinary and human medicines portfolio, Bloomberg reported, citing people familiar with the matter. A sale could value Amoun at $700 million to $800 million, Bloomberg reported. Should Amoun fail to find a buyer, it may consider an...

  • Favorite picks of Tepper, other big hedge honchos Wednesday, 20 May 2015 | 6:00 AM ET
    David Tepper, founder of Appaloosa Management

    With data from the latest SEC filings, CNBC Pro ran a study of more than 40 prominent hedge funds to find where the big money is placing bets.

  • Valeant CEO expects sharp rise in Asia revenue by 2020 Tuesday, 19 May 2015 | 1:04 PM ET

    MONTREAL, May 19- Valeant Pharmaceuticals International Inc's exposure to Asia's growing middle class could help lead to the quintupling of sales in that market to around $5 billion by 2020, Chief Executive Michael Pearson said on Tuesday. Asia, which is expected to generate about $1 billion in sales this year, "has the best growth prospects of any region in the...

  • Hedge funds are beating the S&P 500; here's how Monday, 18 May 2015 | 4:02 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Stock-picking hedge funds are finally beating low-cost equity index funds this year—here's how the best did it.

  • May 18- TPG Capital LP may have helped its own campaign to go public after pulling Par Pharmaceutical Holdings Inc's IPO. TPG was preparing to begin an IPO investor roadshow for Par Pharmaceutical Holdings before it agreed to sell the generics drugmaker to Endo International Plc for around $8 billion. Founded in 1992 by David Bonderman and James Coulter, San...

  • BOSTON, May 15- Wall Street's savviest investors are picking sides on Bill Ackman's new bet on Valeant Pharmaceuticals International Inc, with BlueMountain Capital and T. Rowe Price adding money, while Viking Global Investors and Jana Partners cut stakes. T. Rowe Price bought an additional 2.3 million Valeant shares, raising its stake 12 percent to 20.1 million...

  • *Actavis initial forecast historically conservative- analysts. Sales of Allergan products for 15 days and the drugs acquired with the Forest Laboratories deal helped Actavis beat revenue estimate in the quarter ended March 31. Actavis, whose shares were up 3 percent, outbid Canadian drugmaker Valeant Pharmaceuticals International Inc and activist...

  • Top hedge funds of April and what they're buying Tuesday, 5 May 2015 | 1:12 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Despite a lackluster market, some hedge funds trounced the S&P 500 in April. Here's how they did it.

  • Biotech's torrid run may not be over, analyst says Friday, 1 May 2015 | 3:40 PM ET
    Biotech pharmaceuticals

    Biotech's "great run" will continue despite a bumpy April, which came on the heels of a big jump in the sector, one analyst said.

  • The company said it expects 2015 revenue of $10.4- $10.6 billion, up from its previous estimate of $9.2- $9.3 billion. Valeant, which lost a bid for Botox maker Allergan Inc in November, said sales from the United States rose to $1.40 billion in the first quarter ended March 31. Net income attributable to shareholders was $73.7 million, or 21 cents per share, in the...

  • Valeant Pharma posts profit, says CFO to step down Wednesday, 29 Apr 2015 | 6:28 AM ET

    April 29- Canadian drugmaker Valeant Pharmaceuticals International Inc reported a quarterly profit, compared with a year-ago loss, driven by higher demand in the United States. The company also said Chief Financial Officer Howard Schiller would step down. Net income attributable to shareholders was $73.7 million, or 21 cents per share, in the first quarter...